Find the latest news and updates on InfoBionic and our transformative MoMe® Kardia remote patient monitoring system for cardiac arrhythmia detection and monitoring.

    Stay updated on the market dynamics that are driving change in the healthcare ecosystem, and the innovation behind InfoBionic’s MoMe® Kardia, the first and only Cloud-based arrhythmia detection and monitoring platform to deliver on-demand, actionable analytics reporting directly to those providing patient care – the physicians themselves.

    July 27, 2016

    Frost & Sullivan Honors InfoBionic for New Product Innovation

    Based on its recent analysis of the arrhythmia detection and monitoring market, Frost & Sullivan recognizes InfoBionic with the 2016 North America Frost & Sullivan Award for New Product Innovation. InfoBionic’s MoMe® Kardia system plugs the gaps in traditional cardiac arrhythmia detection devices by optimizing its clinical utility for patients and physicians alike. MoMe Kardia is a wireless remote monitoring system that aids in the detection, management, and diagnosis of cardiac arrhythmias.

    Read More
    July 21, 2016

    InfoBionic Successfully Resolves Obsolete Patent Claims

    Lightweight, Sleek 3-in-1 MoMe® Kardia Device Transforms Cardiac Arrhythmia Detection and Monitoring Lowell, MA, July 21, 2016 — InfoBionic, Inc. today announced that BioTelemetry, Inc. and InfoBionic agreed to dispose of BioTelemetry’s obsolete claims of patent infringement against a first-generation device. InfoBionic is pleased to offer its state-of-the-art, FDA-cleared second-generation MoMe® Kardia System to physicians. After a study showed patients did not like using a two-piece device, InfoBionic decided in August  last year not to commercialize its first-generation MoMe® Kardia device.    InfoBionic and BioTelemetry entered into a judgment in the District of Massachusetts resolving BioTelemetry’s patent claims against this first-generation device. …

    Read More
    March 16, 2016

    InfoBionic Receives FDA 510(k) Clearance for MoMe® Kardia

    InfoBionic, Inc. today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for MoMe® Kardia, a wireless, remote monitoring system designed to aid physicians in their diagnosis of cardiac arrhythmias in patients with a demonstrated need for cardiac monitoring.

    Read More
    August 5, 2015

    InfoBionic Announces $8 Million Series B-1 Financing

    InfoBionic today announced an $8 million Series B-1 financing led by Safeguard Scientifics (NYSE:SFE) with participation from existing shareholders Excel Venture Management; Zaffre Investments, a subsidiary of Blue Cross Blue Shield of Massachusetts; and various angels.

    Read More
    November 19, 2014

    InfoBionic $17M Series B Close + New Team Members

    InfoBionic announced that it closed its $17 million Series B financing round, adding new investors Excel Venture Management and Zaffre Investments. In addition, InfoBionic named Steven R. Wasserman as Chief Financial Officer and William G. Swavely as Senior Vice President, IT.

    Read More
    April 8, 2014

    InfoBionic Raises $17M Series B Financing Led By Safeguard Scientifics

    InfoBionic announced that it has closed the first tranche of a $17 million Series B financing, which was led by Safeguard Scientifics, Inc. (NYSE: SFE). Previous investors—Mass Medical Angels (MA2), Broadview Ventures, TiE, Beta Fund, Boardwalk, Launchpad Venture Group, Cherrystone TCA, HTC, Boynton, and Keiretsu—also contributed to the round. Proceeds from the financing will enable InfoBionic to commercialize its MoMe™ System, a remote patient monitoring platform for cardiac arrhythmia detection, in Europe and the United States.

    Read More
    January 8, 2014

    InfoBionic Announces CE Mark of the MoMe™ System for Remote Patient Monitoring for Cardiac Arrhythmias

    InfoBionic has announced receipt of CE Mark for the MoMe® System for cardiac arrhythmia monitoring. The MoMe System is the first universal remote patient monitoring platform with seamless transition between Holter, Event, and Mobile Cardiac Telemetry (MCT) modes. The innovative platform, which leverages Cloud computing and proprietary analytics, is poised to revolutionize the $3B worldwide cardiac monitoring market by delivering on-demand access to patient data for diagnosis.

    Read More